Publications by authors named "P Airo"
Article Synopsis
- Lung transplantation (LuTx) is a crucial treatment for patients with systemic sclerosis (SSc) and severe lung disease, aiming to improve survival and overall health outcomes.
- A study of 13 SSc patients who underwent LuTx showed significant improvements in lung function, skin involvement, and overall disease activity over a two-year period.
- The survival rate at two years post-transplant was 92.3%, indicating LuTx is a promising option for SSc patients in advanced stages of the disease, with no unexpected adverse events reported.
Background: Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).
Methods: A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (ie mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity % predicted (ppFVC) were assessed for up to 5 years follow-up comparing patients who started early (disease duration ≤ 3 years) vs late with immunosuppression.
Article Synopsis
- Scientists wanted to see how smoking affected people with a disease called systemic sclerosis (SSc).
- They studied over 12,000 patients and found that smoking was linked to worse health outcomes, especially for women.
- Smokers had a higher risk of serious issues like skin problems and even death compared to non-smokers, especially when they had specific antibodies.
Objectives: to report real-life data on rituximab retention-rate as indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients.
Methods: SSc patients treated with rituximab and followed for at least 36 months were included, clinically characterized, and longitudinally monitored. A competing risk analysis with sub-Hazard Ratio(sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation.
Background: The anti-Nucleolar Organizer Region 90 antibodies (NOR90) are rare antinuclear antibodies (ANA) reported in systemic sclerosis (SSc). Especially due to low prevalence, the clinical relevance of NOR90 in SSc remains uncertain.
Objectives: To analyze the clinical associations of NOR90 in patients with SSc in a multicentric cohort.